| |
Bromfenac |
Nepafenac |
|
Bromfenac |
Nepafenac |
| Total Enrolled |
103 |
102 |
Comorbidities |
| Completed |
88 |
85 |
Diabetic |
29 (33%) |
30 (35.3%) |
| Lost to F/U |
15 |
17 |
ARMD |
19 (21.6%) |
22 (25.9%) |
| Average Age |
69.39 ± 9.15 |
68.52 ±9.28 |
POAG |
21 (23.9%) |
24 (28.2%) |
| Age Range |
40-85 |
41-84 |
GS/OHTN |
11 (12.5%) |
9 (10.6%) |
| Sex |
|
|
ERM |
2 (2.27%) |
2 (2.35%) |
| Male |
38 (43.2%) |
49 (57.6%) |
Other |
14 (15.9%) |
12 (14.1%) |
| Female |
50 (56.8%) |
36 (42.4%) |
ARMD = age-related macular edema
POAG = primary open angle glaucoma
GS/OHTN = glaucoma suspect/ocular hypertension
ERM = epiretinal membrane |
| Eyes |
|
|
| OD |
52 (59.1%) |
43 (50.6%) |
| 0S |
36 (40.9%) |
42 (49.4%) |
|
